癌痛消对肝细胞癌缺氧微环境细胞因子HIF-1α、VEGF及PHD2的调节作用的研究
|
摘要
目的：从微环境角度,通过体内试验和体外实验,研究癌痛消通过调节肝细胞癌缺氧微环境中细胞因子HIF-1α、VEGF及PHD2的表达水平治疗肝癌的机理。
方法：1体内试验：采用适宜临床研究的Walker-256移植性肝癌大鼠模型。采用ELISA方法观察癌痛消高、中、低剂量组对移植性肝癌模型大鼠血清AFP、HIF-1α、VEGF表达水平的影响；采用免疫组织化学法、蛋白印迹法、实时荧光定量PCR法,分别观察癌痛消对移植性肝癌模型大鼠肝癌旁组织HIF-1α、VEGF及PHD2表达水平的影响。2体外实验：制备癌痛消高、中、低剂量及5-FU含药血清,采用蛋白印迹法观察癌痛消对缺氧微环境微血管内皮细胞(HMEC-1)中HIF-1α、VEGF及PHD2蛋白表达水平的影响。
结果：1体内试验：癌痛消各组均可以明显抑制血清中AFP、 HIF-1α、VEGF的表达水平；癌痛消各组对肝癌旁组织中HIF-1α、 VEGF及PHD2蛋白和基因的表达均有调节作用,在缺氧微环境中过表达的HIF-1α、VEGF的蛋白和基因均有不同程度的下调,而缺氧微环境中低表达水平的PHD2蛋白和基因均有不同程度的提高,其中癌痛消高剂量组疗效较为显著。
2体外试验：癌痛消高、中、低剂量含药血清作用于缺氧微环境HMEC-1后,结果显示癌痛消各组HMEC-1细胞中的HIF-1α、 VEGF蛋白的表达显著低于模型组；癌痛消各组HMEC-1细胞中PHD2蛋白的表达显著高于模型组,其中癌痛消高剂量组效果最显著。
结论：1癌痛消可降低移植性肝癌模型大鼠血清中AFP、HIF-1α、 VEGF的表达量,以癌痛消高剂量组效更佳。
2癌痛消可降低移植性肝癌模型大鼠肝癌旁织中HIF-1α、VEGF蛋白和基因的过表达,提升PHD2蛋白和基因的低表达,其中癌痛消高剂量组疗效较为显著。
3癌痛消含药血清可降低缺氧微环境HMEC-1中HIF-1α、 VEGF蛋白过表达、提升PHD2蛋白的低表达,其中癌痛消高剂量组疗效较为显著。癌痛消通过调节肝细胞癌缺氧微环境中细胞因子HIF-1α、VEGF及PHD2的表达水平治疗肝癌。
Objective:To study on the mechanism of liver cancer treatment, from the perspective of the microenvironment, that Aitongxiao regulate the expression levels of hepatocellular carcinoma cytokines HIF-la, VEGF and PHD2in the hypoxic microenvironment, via vivo and vitro experiments.
Methods:1vivo experiment:We used Walker-256transplanted liver cancer model rats which was appropriate for clinical studies. We observed the effects what Aitongxiao high, medium and low dose made to the expressions of serum AFP, HIF-1α and VEGF of transplanted liver cancer model rats by ELISA. We observed the expressions of HIF-1α, VEGF and PHD2by immunohistochemistry, Western blot and real-time quantitative PCR (real-time PCR) method.
2vitro experiment:We prepared the serums containing Aitongxiao high, medium and low dose and5-FU, and used Western blot to observe the impacts Aitongxiao had on HIF-1α, VEGF, PHD2expressions of micro-vascular endothelial cells in hypoxic microenvironment.
Results:1vivo experiment:we could see the expressions of serum AFP, HIF-la and VEGF in Aitongxiao groups could be inhibited. The expressions of HIF-la, VEGF and PHD2in HCC adjacent tissues could be adjusted in Aitongxiao groups. It could also reduce the overexpressed HIF-1α, VEGF protein and gene and improve the low expression of PHD2protein with different degrees in hypoxic microenvironment, especially the Aitongxiao high-dose group.
2vitro experiment:After serum-containing Aitongxiao high, medium and low dose acted on HMEC-1in hypoxic microenvironment, the results showed that the expression of HIF-1α and VEGF protein in the HMEC-1cells in Aitongxiao groups was significantly lower than that in the model group, while the expression of PHD2protein was higher. The Aitongxiao high-dose group had the most significant effect.
Conclusion:1Aitongxiao could reduce the expression of serum AFP, HIF-1α and VEGF in the transplanted liver cancer model rats, especially the Aitongxiao high-dose group.
2Aitongxiao could depress over-depression of HIF-1α, VEGF protein and gene in the hypoxic microenvironment, and increase low-expression of PHD2protein and genic. The Aitongxiao high-dose group performed the best among all model groups.
3Serum containing Aitongxiao granules could depress over-depression of HIF-1α, VEGF protein and gene in HMEC-1, and increase low-expression of PHD2protein. Among all the Aitongxiao groups, the high-dose performed the best. Aitongxiao could regulate the expression of cytokines HIF-1α, VEGF and PHD2in the hypoxic microenvironment so as to exert its therapeutic effect.
方法：1体内试验：采用适宜临床研究的Walker-256移植性肝癌大鼠模型。采用ELISA方法观察癌痛消高、中、低剂量组对移植性肝癌模型大鼠血清AFP、HIF-1α、VEGF表达水平的影响；采用免疫组织化学法、蛋白印迹法、实时荧光定量PCR法,分别观察癌痛消对移植性肝癌模型大鼠肝癌旁组织HIF-1α、VEGF及PHD2表达水平的影响。2体外实验：制备癌痛消高、中、低剂量及5-FU含药血清,采用蛋白印迹法观察癌痛消对缺氧微环境微血管内皮细胞(HMEC-1)中HIF-1α、VEGF及PHD2蛋白表达水平的影响。
结果：1体内试验：癌痛消各组均可以明显抑制血清中AFP、 HIF-1α、VEGF的表达水平；癌痛消各组对肝癌旁组织中HIF-1α、 VEGF及PHD2蛋白和基因的表达均有调节作用,在缺氧微环境中过表达的HIF-1α、VEGF的蛋白和基因均有不同程度的下调,而缺氧微环境中低表达水平的PHD2蛋白和基因均有不同程度的提高,其中癌痛消高剂量组疗效较为显著。
2体外试验：癌痛消高、中、低剂量含药血清作用于缺氧微环境HMEC-1后,结果显示癌痛消各组HMEC-1细胞中的HIF-1α、 VEGF蛋白的表达显著低于模型组；癌痛消各组HMEC-1细胞中PHD2蛋白的表达显著高于模型组,其中癌痛消高剂量组效果最显著。
结论：1癌痛消可降低移植性肝癌模型大鼠血清中AFP、HIF-1α、 VEGF的表达量,以癌痛消高剂量组效更佳。
2癌痛消可降低移植性肝癌模型大鼠肝癌旁织中HIF-1α、VEGF蛋白和基因的过表达,提升PHD2蛋白和基因的低表达,其中癌痛消高剂量组疗效较为显著。
3癌痛消含药血清可降低缺氧微环境HMEC-1中HIF-1α、 VEGF蛋白过表达、提升PHD2蛋白的低表达,其中癌痛消高剂量组疗效较为显著。癌痛消通过调节肝细胞癌缺氧微环境中细胞因子HIF-1α、VEGF及PHD2的表达水平治疗肝癌。
Objective:To study on the mechanism of liver cancer treatment, from the perspective of the microenvironment, that Aitongxiao regulate the expression levels of hepatocellular carcinoma cytokines HIF-la, VEGF and PHD2in the hypoxic microenvironment, via vivo and vitro experiments.
Methods:1vivo experiment:We used Walker-256transplanted liver cancer model rats which was appropriate for clinical studies. We observed the effects what Aitongxiao high, medium and low dose made to the expressions of serum AFP, HIF-1α and VEGF of transplanted liver cancer model rats by ELISA. We observed the expressions of HIF-1α, VEGF and PHD2by immunohistochemistry, Western blot and real-time quantitative PCR (real-time PCR) method.
2vitro experiment:We prepared the serums containing Aitongxiao high, medium and low dose and5-FU, and used Western blot to observe the impacts Aitongxiao had on HIF-1α, VEGF, PHD2expressions of micro-vascular endothelial cells in hypoxic microenvironment.
Results:1vivo experiment:we could see the expressions of serum AFP, HIF-la and VEGF in Aitongxiao groups could be inhibited. The expressions of HIF-la, VEGF and PHD2in HCC adjacent tissues could be adjusted in Aitongxiao groups. It could also reduce the overexpressed HIF-1α, VEGF protein and gene and improve the low expression of PHD2protein with different degrees in hypoxic microenvironment, especially the Aitongxiao high-dose group.
2vitro experiment:After serum-containing Aitongxiao high, medium and low dose acted on HMEC-1in hypoxic microenvironment, the results showed that the expression of HIF-1α and VEGF protein in the HMEC-1cells in Aitongxiao groups was significantly lower than that in the model group, while the expression of PHD2protein was higher. The Aitongxiao high-dose group had the most significant effect.
Conclusion:1Aitongxiao could reduce the expression of serum AFP, HIF-1α and VEGF in the transplanted liver cancer model rats, especially the Aitongxiao high-dose group.
2Aitongxiao could depress over-depression of HIF-1α, VEGF protein and gene in the hypoxic microenvironment, and increase low-expression of PHD2protein and genic. The Aitongxiao high-dose group performed the best among all model groups.
3Serum containing Aitongxiao granules could depress over-depression of HIF-1α, VEGF protein and gene in HMEC-1, and increase low-expression of PHD2protein. Among all the Aitongxiao groups, the high-dose performed the best. Aitongxiao could regulate the expression of cytokines HIF-1α, VEGF and PHD2in the hypoxic microenvironment so as to exert its therapeutic effect.
引文
[1]Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics[J]. CA Cancer J Clin.2002,55(2):74-108.
[2]Yang J D, Roberts L R. Hepatocellular carcinoma:A global view[J]. Nat Rev Gastroenterol Hepatol.2010,8(7):448-458.
[3]Mbeunkui F, Johann D J, Jr. Cancer and the tumor microenvironment:A review of an essential relationship[J]. Cancer Chemother Pharmacol.2009,63(4):571-582.
[4]Allen M, Louise Jones J. Jekyll and hyde:the role of the microenvironment on the progression of cancer [J]. J Pathol.2011,223(2):162-176.
[5]方伟岗.肿瘤细胞与微环境的相互作用决定肿瘤转移的最终归宿[J].前沿科学.2011,05(3)：4-15.
[6]杜钢军,时小燕.治疗癌症的新途径：靶向肿瘤微环境[J].国际药学研究杂志.2011,38(5)：336-340.
[7]Joyce J A, Pollard J W. Microenvironmental regulation of metastasis. Nat Rev Cancer[J]. Nat Rev Cancer.2009,9(4):239-252.
[8]Liotta L A, Kohn E C. The microenvironment of the tumour-host interface[J]. Nature.2001,411(6835):375-379.
[9]Hede K. Environmental protection:studies highlight importance of tumor microenvironment[J]. J Natl Cancer Inst.2004,96(15):1120-1121.
[10]李世杰.β-catenin在肝细胞癌及乏氧微环境中的研究进展[J].实用肿瘤学杂志.2013,27(4)：372-376.
[11]邱斌玉,温浩,张金辉.肝癌复发转移微环境研究进展[J].肝胆外科杂志.2010,18(1)：62-66.
[12]Albin I, Sporn M B. The tumourm inroenvironment as a target for chemoprevention[J]. Nat Rev Cancer.2007,7:139-147.
[13]Tang C, Yu J. Hypoxia-inducible factor-1 as a therapeutic target in cancer[J]. J Gastroenterol Hepatol.2013,28(3):401-405.
[14]戴陈新.HIF-la对肝癌复发转移及肝癌内外相关微环境的影响[D].上海：复旦大学,2010.
[15]Gup Ta G, Massague J. Cancer metastasis:building a framework[J]. Cell.2006,127:679-695.
[16]Baldewijns M, Thijssen V, Van den Eynden G, et al. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quanti fication and qRT-PCR mRNA expression profile[J]. Br J Cancer.2007, 96(12):1888-1895.
[17]吴丽花,郑树森.缺氧诱导因子-1的调控(文献综述)[J].国外医
学(外科学分册).2004,31(6)：347-351.[18] Tanaka T, Nangaku M. Angiogenesis and hypoxia in the kidney [J]. Nat Rev Nephrol.2013,9(4):211-222.
[19]Liu L, Sun L, Zhang H, et al. Hypoxia-mediated up-regulation of MGrl-Ag/37LRP in gastric cancers occurs via hypoxia-inducible-factor 1-dependent mechanism and contributes to drug resistance[J]. Int J Cancer.2009,124(7):1707-1715.
[20]Folkman J. Tumor angiogenesis and tissue factor[J]. Nat Med.1996, 2(2):167-168.
[21]von Marschall Z, Cramer T, Hcker M, et al. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma[J]. Gut.2001,48(1):87-96.
[22]Kitano H. Cancer as a robust system:implications for anticance therapy [J] [J]. Nat Rev Cancer.2004,4(3):227-235.
[23]Catalan V, Gomez-Ambrosi J, Rodriguez A, et al. Up-regulation of the novel roinflammatory adipokines lipocalin-2, chitinase-3 like-1 and osteopontin as well as angiogenic-related factors in visceral adipose tissue of patients with colon cancer[J].[J]. J Nutr Biochem.2011,22(7): 634-641.
[24]Denekamp J. Review article:Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy [J]. Br J Radiol. 1993,66(783):181-196.
[25]朱诚程.脯氨酸羟化酶在妇科肿瘤中的研究进展[J].现代妇产科进展.2011,20(10)：831-832,835.
[26]Metzen E, Stiehl D, Do Ege K, et al. Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene:identification of a functional hypoxia responsive element[J]. Biochem J.2005,387(3):711.
[27]夏冰清,杨帆,张硕,等.脯氨酰羟化酶研究进展及其与肿瘤的关系[J].南通大学学报(医学版).2010,30(2)：142-145,147.
[28]Semenza G. Singnal transduction to hypoxia-inducible tactor[J]. Biochem Pharmacol.2002,64(5-6):993-998.
[29]韦艾凌,官志杰,邱华.初论毒浊与原发性肝癌的发病[J].辽宁中医杂志.2009,36(7)：1088-1089.
[30]李运伦.毒邪的源流及其分类诠释[J].中医药学刊.2001,18(1)：44-45.
[31]邱丙庆.论毒邪[J].中医药学报.2013,41(4)：7-9.
[32]郑洪新.中医病因新说——环境毒邪[J].辽宁中医杂志.2002,29(2)：63-64.
[33]刘震,姚乃礼.慢性乙型肝炎、肝硬化毒邪致病的古今认记[J].中医药学报.2005,33(6)：56-57.
[34]张杰,章天寿.从“虚”“毒”“瘀”论治慢性萎缩性胃炎[J].中国中医基础医学杂志.2005,11(1)：44-45.
[35]乐鸣.SARS毒邪内闭的证治探析[J].实用中医内科杂志.2004,18(3)：193.
[36]黄世敬.论”毒”与艾滋病的发病[J].中国中医基础医学杂志.2004,10(7)：46-47.
[37]雷燕,王永炎,黄启福.络病理论探微[J].北京中医药大学学报.1998,21(2)：18-23.
[38]王永炎.关于提高脑血管疾病疗效的思考[J].中国中西医结合杂志.1997,17(2)：195-196.
[39]凌昌全.”癌毒”是恶性肿瘤之根本[J].中西医结合学报.2008,6(2)：111-114.
[40]何立丽,孙桂芝.孙桂芝治疗肺癌经验[J].北京中医药.2009,
28(4)：263-264.[41]郁仁存.中西医结合肿瘤学[M].1.北京：中国协和医科大学出版社,2008.
[42]李忠,刘丹,刘杰,等.肿瘤中医“耗散病机假说”的建立和固摄法的提出[J].南京中医药大学学报.2006,22(3)：140-142.
[43]梁玉莹,黎静.痰证与细胞黏附因子在肿瘤转移机制中的相似性初探[J].新中医.2006,38(12)：5-7.
[44]Cho Sj Y J H S, Hepatol. G L. Do young hepatorcellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients?[J]. J Gastroentero 1 Hepatol.2007,22(8):1226-1231.
[45]王振元,唐小华,刘胜雄,等.不同年龄结直肠癌患者临床及内镜特点分析[J].中国基层医药.2006,13(7)：1173-1174.
[46]陈军,徐祗顺,张怡,等.年龄因素与成人肾恶性肿瘤临床发病特点的关系[J].中华泌尿外科杂志.2006,27(2)：93-96.
[47]蔡善荣,郑树,张苏展.不同年龄组大肠癌预后多因素分析的比较[J].中华肿瘤杂志.2005,27(8)：483-485.
[48]汤钊猷.临床肝癌学[M].1.上海：上海科技教育出版社,2001.
[49]魏睿,王宪波.中医药辨治原发性肝癌：病理因素及用药特点分析[J].中西医结合肝病杂志.2013,23(2)：117-120.
[50]郭建辉.周仲瑛教授“癌毒学说”新论[J].湖南中医药大学学报.2010,30(11)：6-8.
[51]吴以岭.络病学[M].1.北京：中国科学出版社,2004.
[52]魏睿,王宪波.中医药辨治原发性肝癌：病理因素及用药特点分析[J].中西医结合肝病杂志.2013,23(2)：117-120.
[53]陈赐慧,花宝金.肿瘤炎性微环境与中医阴阳动态平衡关系初探[J].中医杂志.2012,53(19)：1626-1628,1650.
[54]丛玉隆,王淑娟.今日临床检验学[M].1.北京：中国科学技术出版社,1997.
[55]Bingle L, Lewis C, Corker K, et al. Macrophages promote angiogeresis in hrman breast tumour spheroids in vivo[J]. Br J Cancer. 2006,94(1):101-107.
[56]van den Beucken T, Ramaekers C, Rouschop K, et al. Deficient carbonic anhy2drase 9 expression in UPR2impaired cells is associated with reduced survival in an acidic microenvironment[J]. Radiother Oncol. 2009,92(3):437-442.
[57]李以义.痰浊与癌症[J].中国中医基础医学杂志.1995,1(4)：46-47.
[58]王剑,严灿,邓中炎.从粘附分子代谢失常探讨痰证机理[J].中国中西医结合杂志.2000,20(4)：296.
[59]魏录翠,韦艾凌,唐健,等.癌痛消颗粒调节大鼠移植性肝癌VEGF和MVD表达的实验研究[J].辽宁中医药大学学报.2008,10(8)：159-161.
[60]费新应,黄廷荣,沈震,等.膈下逐瘀汤辅助治疗原发性肝癌的临床观察[J].湖北中医杂志.2006,28(1)：34.
[61]韦艾凌,唐健,陈逸恒,等.癌痛消颗粒治疗原发性肝癌血瘀毒结兼正虚证疗效分析[J].辽宁中医杂志.2007,34(5)：570-572.
[62]王庆高,韦艾凌,徐志新.广西中医药[J].2005,28(2)：45-48.
[63]贾中芝,冯耀良,施海彬.原发性肝癌TACE前后血清HIF-1α与VEGF的相关性[J].中国介入影像与治疗学.2010,7(2)：117-120.
[64]黄峰.基于“治未病”思想的癌痛消方防治大鼠诱导性肝癌的实验研究[D].湖南：湖南中医药大学,2013.
[65]刘亚梅.中医热证本质研究进展及思考[J].安徽中医学院学报.1999,18(2)：54-58.
[66]Zhang Y, Wang S, Li Y, et al. Sophocarpine and matrine inhibit the production of TNF-alpha and IL-6 inmurine macrophages and prevent cachexia-related symptoms induced by colon 26 adenocarinoma in mice [J]. Int Immunopharmacol.2008,8(13-14):1767-1772.
[67]Chen X, Mellon R, Yang L, et al. Regulatory effects of deoxycholic acid, a componet if the anti-inflammatory traditional Chinese medicine Niuhuang, on human leukocyte response to chemoattractants[J]. Biochem Pharmacol.2002,63(3):533-541.
[68]丁志山,高承贤,陈铌铍,等.姜黄素具有抑制血管生成与诱导肿瘤细胞凋亡双重作用[J].中国药理学通报.2003,19(2)：171-173.
[69]刘锦蓉,叶松柏.川芎嗪抗肿瘤转移作用及其机理[J].中国药理学与毒理学杂志.1993,7(02)：149-152.
[70]黄孔威,傅乃武.赤芍对实验肿瘤生长和转移的影响及药理作用 的研究[J].中华肿瘤杂志.1983,5(1)：24-27.
[71]郑红刚,朴炳奎,林洪生,等.肺瘤平膏对非小细胞肺癌患者树突状细胞亚型及免疫功能的影响[J].北京中医.2007,26(4)：214-217.
[72]朱峰,杨小伟,汤永辉,等.Walker-256大鼠移植性肝癌模型探讨[J].医学研究杂志.2010,39(9)：92-93.
[73]袁利超,党双锁,程延安.肝癌的靶向治疗[J].世界最新医学信息文摘.2003,2(6)：881-883.
[74]马曾辰.可供临床研究的常用鼠肝癌模型[J].国外医学肿瘤学分册.1982,1(1)：13.
[75]Bertout J A, Patel S A, Simon M C. The impact of 02 availability on human cancer[J]. Nat Rev Cance.2008,8(12):967-975.
[76]Simon J M. Hypoxia and angiogenesis[J]. Bull Cancer.2007.
[77]Vooijs M A, Gort E H, Groot A J, et al. Hypoxic regulation of metastasis viaHypxxia-inducible factors[J]. Curr Mol Med.2008,8(1): 60-67.
[78]Vengellur A, Phillips J M, Hogenesch J B, et al. Gene expression profiling of hypoxia signaling in human hepatocellular carcinoma cells [J]. 2005,22(3):308-318.
[79]Covello K L, Simon M C, Keith B. Targeted replacement of hypoxia-inducible factor-2alpha by a hypoxia inducible factor-2alpha knock in allele promotes tumor growth[J]. Cancer Res.2005,65(6): 2277-2286.
[80]Miyoshi A, Kitajima Y, Ide T, et al. Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1 α-independent manner[J]. Int J Oncol.2006,29(6):1533-1539.
[81]Esteban M A. Regulation of E-cadherin expression byVAL and hypoxia-inducible factor[J]. Cancer Res.2006,66(7):3567-3575.
[82]Mathonnet M, Descottes B, Valleix D, et al. Quantitative analysis using ELISA of vascular endothelial growth factor and basic fibroblast growth factor in human colorectal cancer, liver metastasis of colorectal cancer and hepatocellular carcinoma[J]. World J Gastroenterol.2006, 12(23):3782-3783.
[83]Vumbaca F, Phoenix K N, Rodriguez-Pinto D, et al. Double-Stranded RNA-Binding Protein Regulates Vascular Endothelial Growth Factor mRNA Stability, Translation, and Breast Cancer Angiogenesis.2008,28(2):772-783.
[84]黄峰,韦艾凌.癌痛消颗粒对移植性肝癌模型大鼠肝癌组织mi RNAs表达的影响[J].中国药学杂志.2013,48(20)：1740-1743.
[85]韩克起,凌昌全.中药体外抗肿瘤效应血清药理学研究现状与前景[J].中国中西医结合杂志.2003,23(9)：717-719.
[86]Yan M., Rayoo M., Takano Ea. BRCAI tumours eorrelate with a HIF-1 alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression[J]. Br J Cancer.2009,101(7): 1168-1174.
[87]吕修臣,刘俊莉,张琼霞,等.中西医结合强化综合治疗原发性肝癌临床研究[J].中国中西医结合急救杂志.2001,8(5)：306-308.
[88]Breier G, Licht A H, Nicolaus A, et al. HIF in vascular development and tumour angiogenesis[J]. Novartis Found Symp.2007,283:126-133.
[89]Esteban M A, Tran M G B, Harten S K, et al. Regulation of E-cadherin Expression by VHL and Hypoxia-Inducible Factor[J]. Cancer Res.2006,66(7):3567-3575.
[90]Miyoshi A, Kitajima Y, Ohtaka K, et al. Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MM expression in an HIF-1 α-independent manner[J]. Int J Oncol.2006,29(6):1533-1539.
[91]Park Y, Kin Y. Inereased exppression of vaseular endothelial growth faetor and angiogenesis in the early stage of multistep hepatoeareinogenesis [J]. Arch Pattol Lab Med.2000,124(7):61-106.
[92]盛庆丰,咸华,印其友.二氯化钴诱导大鼠肝癌细胞缺氧与凋亡和增殖的研究[J].南通大学学报(医学版).2008,28(5)：324-325,328.
[1]Whittaker S, Marais R, Zhu A. The role of signaling pathways in the development and treatment of hepatocellular carcinoma[J]. Oncogene. 2010,29:4989-5005.
[2]Yang J, Roberts L. Hepatocellular carcinoma:a global view[J]. Nat Rev Gastroenterol Hepatol.2010,7(8):448-458.
[3]张焕荣,张俊芳,张培帅.肝细胞癌的诊治进展[J].中国当代医药.2012,19(20)：16-18.
[4]韩泽广.肝癌基因组学研究进展[J].中国科学(C辑：生命科学).2008,38(10)：907-912.
[5]Ahmed R, Salama H, Fouad A, et al. Detection of aberrant p16INK4A methylation in sera of patients with HCV-related liver diseases:An Egyptian study[J]. Med Sci Monit.2010,16(9):R410-R415.
[6]Nakagawa T, Kanai Y, Ushijima S, et al. DNA hypomethylation on pericentromeric satellite regions significantly correlates with loss of heterozygosity on chromosome 9 in urothelial carcinomas [J]. J Urol. 2005,173(1):243-246.
[7]Wong N, Lam W, Lai P, et al. Hypomethylation of Chromosome 1 Heterochromatin DNA Correlates with q-Arm Copy Gain in Human Hepatocellular Carcinoma[J]. Am J Pathol.,159(2):465-471.
[8]Guo M, Ren J, Qi M H, et al. Accumulation of Promoter Methylation Suggests Epigenetic Progression in Squamous Cell Carcinoma of the Esophagus[J]. Clin Cancer Res.2006,12(15): 4515-4522.
[9]王勇.肝癌DNA甲基化的研究进展[J].医学综述.2011,17(22)：3404-3406.
[10]Trankenschuh W, Puls F, Christgen M, et al. Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver[J]. PLoS One.2010,5(10):136-188.
[11]Formeister E, Tsuchiya M, Fujii H, et al. Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma[J]. Mutat Res.2010,692(1/2):26-33.
[12]颜见,姚志成,邓美海.乙型肝炎病毒相关性肝癌发生的分子机制研究进展[J].中华普通外科学文献(电子版).2012,06(5)：50-54.
[13]Gu J, Tamura M, Yamada K. Tumor suppressor PTEN inhibits integrin-and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways[J]. J Cell Biol.1998,143(5):1375-1383.
[14]Zhu X, Zhou F, Qin D, et al. Human Immunodeficiency Virus Type 1 Induces Lytic Cycle Replication of Kaposi's-Sarcoma-Associated Herpesvirus:Role of Ras/c-Raf/MEK1/2, PI3K/AKT, and NF-κB Signaling Pathways[J]. J Mol Biol.2011,410(5):1035-1051.
[15]Gomes C, Diniz M, Oliveira C, et al. Impact of WWOX alterations on p73, △Np73, p53, cell proliferation and DNA ploidy in salivary gland neoplasms[J]. Oral Dis.2011,17(6):551-564.
[16]Wang F, Denison S, Lai J, et al. Parkin gene alterations in hepatocellular carcinoma[J]. Genes Chromosomes Cancer.2004,40(2): 85-86.
[17]冯华,任春慧,王凤爽.肝细胞癌发病机制的研究进展[J].牡丹江医学院学报.2007,28(4)：86-88.
[18]Sansal I, Sellers W. The biology and clinical relevance of the PTEN tumor suppressor pathway [J]. J Clin Onco.2004,22(14):2954-2963.
[19]刘志磊,孙薇,贺福初,等.肝细胞癌的微环境研究进展[J].生物化学与生物物理进展.2012,39(05)：416-422.
[20]Bissell M, Hines W. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression[J]. Nat Med. 2011,17(3):320-329.
[21]Mbeunkui F, Johann Jr D. Cancer and the tumor microenvironment: a review of an essential relationship[J]. Cancer Chemother Pharmacol. 2009,63(4):571-582.
[22]Huang G, Chen L. Tumor Vasculature and Microenvironment Normalization:A Possible Mechanism of Antiangiogenesis Therapy [J]. 2008,23(5):661-667.
[23]Hede K. Environmental protection:studies highlight importance of tumor microenvironment[J]. J Natl Cancer Inst.2004,96(15):1120-1121.
[24]Bangoura G, Liu Z, Qian Q, et al. Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma[J]. World J Gastroenterol.2007,13(23):3176-3182.
[25]Gwak G, Yoon J, Kim K, et al. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression[J]. J Hepatol.2005,42(3):358-364.
[26]Kim K, Moon H, Kim K. Hypoxia-induced angiogenesis in human hepatocellular carcinoma[J]. J Mol Med.2002,80(11):703-704.
[27]Miyoshi A, Kitajima Y, Ide T, et al. Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1 α-independent manner[J]. Int J Oncol.2006,29(6):1533-2539.
[28]Wu X, Xie G, Chen D. Hypoxia and hepatocellular carcinoma:The therapeutic target for hepatocellular carcinoma[J]. J Gastroentero 1 Hepatol.2007,22(8):1178-1182.
[29]Bertout J, Patel S, Simon M. The impact of 02 availability on human cancer[J]. Nat Rev Cancer.2008,8(12):967-975.
[30]Rosmorduc O, Housse C. Hypoxia:a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease[J]. Semin Liver Dis. 2010,30(3):258-270.
[31]Paternostro C, David E, Novo E, et al. Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases[J]. World J Gastroentero 1.2010,16(3):281-288.
[32]王照红,王志明.肝细胞癌缺氧微环境下PHD2的表达及其与血管生成的关系[J].中国普通外科杂志.2010,19(10)：1113-1117.
[33]Folkman J. Angiogenesis:an organizing principle for drug discovery?[J]. Nat Rev Drug Discov.2007,6:273-286.
[34]Quesada A, Medina M, Alba E. Playing only one instrument may be not enough:limitations and future of the antiangiogenic treatment of cancer[J]. Bioessays.2007,29(11):1159-1168.
[35]Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy[J]. Nat Rev Cancer,2008,8(8):592.2008,8:592-603.
[36]Fukumura D, Jain R. Tumor micro vasculature and microenvironment:targets for anti-angiogenesis and normalization [J]. Microvasc Res.2007,74(2-3):72-84.
[37]Lin M, Sessa W. Antiangiogenic therapy:Creating a unique "window" of opportunity [J]. Cancer cell.2004,6(6):529-531.
[38]Jain R, Duda D, Clark J, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer[J]. Nat Clin Pract Oncol.2006,3(1): 24-40.
[39]Tong R, Boucher Y, Kozin S, et al. Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors[J]. Cancer Res.2004,64(11):3731-3736.
[40]张丽,张华.中医姑息治疗肝癌[J].现代中西医结合杂志.2007,16(11)：1475-1477.
[41]闫建国,姚树坤.中医对原发性肝癌的辨证研究及治疗[J].中西医结合肝病杂志.2010,20(3)：189-191.
[42]黄金昶.原发性肝癌中医治疗体会[J].中国临床医生.2006,34(10)：59-60.
[43]张洪亮,张震中,王登正.肝癌[J].新疆中医药.2005,23(02)：74-76.
[44]谢晶日,赵刚,梁国英.原发性肝癌的中医药现代研究进展[J].中国医药导报.2008,5(7)：17-18.
[45]孙佳,叶丽红.名老中医治疗肝癌经验研究评述[J].中医学报.2012,27(6)：658-660.
[46]王睿林,王立福,王仲霞,等.中药治疗肝癌研究现状[J].传染病信息.2012,25(3)：189-192.
[47]王见义,赵莹,王灵台.王灵台治疗原发性肝癌经验探微[J].上海中医药杂志.2010(02)：20-21.
[48]王昌俊,陈伟.钱伯文治疗原发性肝癌经验[J].中医杂志.1999,40(08)：460-461.
[49]金萍,沈敏鹤.吴良村诊治原发性肝癌经验[J].中医杂志.2005,46(9)：660-661.
[50]陈华良.周岱翰治肝癌临证经验[J].中医杂志.2003,44(12)：894-895.
[51]范先基,杨子玉.王三虎治疗肝癌经验[J].中国中医药信息杂志.2009,16(8)：86-87.
[52]周滢,周萍.邓中甲教授治疗肝癌经验分析[J].中国实验方剂学杂志.2012,18(2)：260-261.
[53]赵冬耕,叶丽红.肝癌中医研究近况[J].辽宁中医药大学学报.2011,13(12)：207-209.
[54]李涵.中医药治疗原发性肝癌的临床应用进展[J].中医临床研究.2012,04(16)：114-117.
[55]侯风刚,凌昌全,赵钢,等.原发性肝癌中医基本证候临床分布状况调查分析[J].上海中医药杂志.2005,39(2)：22-23.
[56]李永健,方肇勤,邸若虹,等.2492例肝癌辨证分型临床报道的统计分析[J].中国中医基础医学杂志.2001,7(6)：69-71.
[57]燕忠生,魏千程,张慧渊,等.原发性肝癌中医证型临床特点与预后关系研究[J].实用中医内科杂志.2006,20(4)：411-412.
[58]庄险峰.“三辨”治肝癌[J].中医临床研究.2012(18)：18-20.
[59]熊智波.益气养阴解毒法治疗原发性肝癌的研究与应用[J].湖北中医杂志.2011,33(4)：68-69.
[60]孙振,王忠.肝癌中医治法研究概述[J].浙江中医药大学学报.2011,35(3)：468-470.
[61]佟晓光,张景洲,惠歌.以通络学说论治肝细胞癌的探讨[J].中国医药指南.2012,10(21)：261-262.
[62]袁菊花,吴煜.肝癌从痰论治[J].新中医.2012,44(03)：131-132.
[63]杨勤龙.大黄甲虫汤治疗原发性肝癌30例临床报告[J].黑龙江中医药.2001,10(05)：28-29.
[64]彭海燕,章永红,王瑞平,等.补肝软坚方治疗肝癌100例临床观察[J].北京中医.2004,23(1)：30-31.
[65]傅理琦.扶正抑瘤汤治疗晚期肝癌42例临床观察[J].浙江中医杂志.2001,36(9)：375-376.
[66]李江,谢鸣,甘媛.小柴胡汤及其药群配伍抗小鼠H22肝肿瘤及免疫调节作用[J].中国中药杂志.2008,33(9)：1039-1044.
[67]季幸妹,周小军,侯丽颖,等.膈下逐瘀汤对肝癌防治的机理研究[J].现代医药卫生.2008,24(12)：1742-1744.
[68]杜标炎,张爱娟,谭宇蕙,等.六味地黄丸对自杀基因系统杀伤肝癌细胞增效作用的量效关系[J].广州中医药大学学报.2009,26(1)：59-62.
[69]刘俊保,姚志伟.白花蛇舌草注射液对原发性肝癌的临床作用[J].医药论坛杂志.2004,25(15)：37,39.
[70]蒋明东,李少林.三氧化二砷与肝癌治疗的研究进展[J].重庆医学.2006,35(6)：558-559,563.
[71]代志军,刘小旭,薛茜,等.半枝莲含药血清对小鼠肝癌细胞生长的抑制和诱导凋亡作用[J].中药材.2008,31(4)：550-553.
[72]荆绪斌,李涛,杨绮华,等.汉防己甲素抑制肝癌细胞增生的作 用[J].世界华人消化杂志.2003,11(8)：1223-1226.
[2]Yang J D, Roberts L R. Hepatocellular carcinoma:A global view[J]. Nat Rev Gastroenterol Hepatol.2010,8(7):448-458.
[3]Mbeunkui F, Johann D J, Jr. Cancer and the tumor microenvironment:A review of an essential relationship[J]. Cancer Chemother Pharmacol.2009,63(4):571-582.
[4]Allen M, Louise Jones J. Jekyll and hyde:the role of the microenvironment on the progression of cancer [J]. J Pathol.2011,223(2):162-176.
[5]方伟岗.肿瘤细胞与微环境的相互作用决定肿瘤转移的最终归宿[J].前沿科学.2011,05(3)：4-15.
[6]杜钢军,时小燕.治疗癌症的新途径：靶向肿瘤微环境[J].国际药学研究杂志.2011,38(5)：336-340.
[7]Joyce J A, Pollard J W. Microenvironmental regulation of metastasis. Nat Rev Cancer[J]. Nat Rev Cancer.2009,9(4):239-252.
[8]Liotta L A, Kohn E C. The microenvironment of the tumour-host interface[J]. Nature.2001,411(6835):375-379.
[9]Hede K. Environmental protection:studies highlight importance of tumor microenvironment[J]. J Natl Cancer Inst.2004,96(15):1120-1121.
[10]李世杰.β-catenin在肝细胞癌及乏氧微环境中的研究进展[J].实用肿瘤学杂志.2013,27(4)：372-376.
[11]邱斌玉,温浩,张金辉.肝癌复发转移微环境研究进展[J].肝胆外科杂志.2010,18(1)：62-66.
[12]Albin I, Sporn M B. The tumourm inroenvironment as a target for chemoprevention[J]. Nat Rev Cancer.2007,7:139-147.
[13]Tang C, Yu J. Hypoxia-inducible factor-1 as a therapeutic target in cancer[J]. J Gastroenterol Hepatol.2013,28(3):401-405.
[14]戴陈新.HIF-la对肝癌复发转移及肝癌内外相关微环境的影响[D].上海：复旦大学,2010.
[15]Gup Ta G, Massague J. Cancer metastasis:building a framework[J]. Cell.2006,127:679-695.
[16]Baldewijns M, Thijssen V, Van den Eynden G, et al. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quanti fication and qRT-PCR mRNA expression profile[J]. Br J Cancer.2007, 96(12):1888-1895.
[17]吴丽花,郑树森.缺氧诱导因子-1的调控(文献综述)[J].国外医
学(外科学分册).2004,31(6)：347-351.[18] Tanaka T, Nangaku M. Angiogenesis and hypoxia in the kidney [J]. Nat Rev Nephrol.2013,9(4):211-222.
[19]Liu L, Sun L, Zhang H, et al. Hypoxia-mediated up-regulation of MGrl-Ag/37LRP in gastric cancers occurs via hypoxia-inducible-factor 1-dependent mechanism and contributes to drug resistance[J]. Int J Cancer.2009,124(7):1707-1715.
[20]Folkman J. Tumor angiogenesis and tissue factor[J]. Nat Med.1996, 2(2):167-168.
[21]von Marschall Z, Cramer T, Hcker M, et al. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma[J]. Gut.2001,48(1):87-96.
[22]Kitano H. Cancer as a robust system:implications for anticance therapy [J] [J]. Nat Rev Cancer.2004,4(3):227-235.
[23]Catalan V, Gomez-Ambrosi J, Rodriguez A, et al. Up-regulation of the novel roinflammatory adipokines lipocalin-2, chitinase-3 like-1 and osteopontin as well as angiogenic-related factors in visceral adipose tissue of patients with colon cancer[J].[J]. J Nutr Biochem.2011,22(7): 634-641.
[24]Denekamp J. Review article:Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy [J]. Br J Radiol. 1993,66(783):181-196.
[25]朱诚程.脯氨酸羟化酶在妇科肿瘤中的研究进展[J].现代妇产科进展.2011,20(10)：831-832,835.
[26]Metzen E, Stiehl D, Do Ege K, et al. Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene:identification of a functional hypoxia responsive element[J]. Biochem J.2005,387(3):711.
[27]夏冰清,杨帆,张硕,等.脯氨酰羟化酶研究进展及其与肿瘤的关系[J].南通大学学报(医学版).2010,30(2)：142-145,147.
[28]Semenza G. Singnal transduction to hypoxia-inducible tactor[J]. Biochem Pharmacol.2002,64(5-6):993-998.
[29]韦艾凌,官志杰,邱华.初论毒浊与原发性肝癌的发病[J].辽宁中医杂志.2009,36(7)：1088-1089.
[30]李运伦.毒邪的源流及其分类诠释[J].中医药学刊.2001,18(1)：44-45.
[31]邱丙庆.论毒邪[J].中医药学报.2013,41(4)：7-9.
[32]郑洪新.中医病因新说——环境毒邪[J].辽宁中医杂志.2002,29(2)：63-64.
[33]刘震,姚乃礼.慢性乙型肝炎、肝硬化毒邪致病的古今认记[J].中医药学报.2005,33(6)：56-57.
[34]张杰,章天寿.从“虚”“毒”“瘀”论治慢性萎缩性胃炎[J].中国中医基础医学杂志.2005,11(1)：44-45.
[35]乐鸣.SARS毒邪内闭的证治探析[J].实用中医内科杂志.2004,18(3)：193.
[36]黄世敬.论”毒”与艾滋病的发病[J].中国中医基础医学杂志.2004,10(7)：46-47.
[37]雷燕,王永炎,黄启福.络病理论探微[J].北京中医药大学学报.1998,21(2)：18-23.
[38]王永炎.关于提高脑血管疾病疗效的思考[J].中国中西医结合杂志.1997,17(2)：195-196.
[39]凌昌全.”癌毒”是恶性肿瘤之根本[J].中西医结合学报.2008,6(2)：111-114.
[40]何立丽,孙桂芝.孙桂芝治疗肺癌经验[J].北京中医药.2009,
28(4)：263-264.[41]郁仁存.中西医结合肿瘤学[M].1.北京：中国协和医科大学出版社,2008.
[42]李忠,刘丹,刘杰,等.肿瘤中医“耗散病机假说”的建立和固摄法的提出[J].南京中医药大学学报.2006,22(3)：140-142.
[43]梁玉莹,黎静.痰证与细胞黏附因子在肿瘤转移机制中的相似性初探[J].新中医.2006,38(12)：5-7.
[44]Cho Sj Y J H S, Hepatol. G L. Do young hepatorcellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients?[J]. J Gastroentero 1 Hepatol.2007,22(8):1226-1231.
[45]王振元,唐小华,刘胜雄,等.不同年龄结直肠癌患者临床及内镜特点分析[J].中国基层医药.2006,13(7)：1173-1174.
[46]陈军,徐祗顺,张怡,等.年龄因素与成人肾恶性肿瘤临床发病特点的关系[J].中华泌尿外科杂志.2006,27(2)：93-96.
[47]蔡善荣,郑树,张苏展.不同年龄组大肠癌预后多因素分析的比较[J].中华肿瘤杂志.2005,27(8)：483-485.
[48]汤钊猷.临床肝癌学[M].1.上海：上海科技教育出版社,2001.
[49]魏睿,王宪波.中医药辨治原发性肝癌：病理因素及用药特点分析[J].中西医结合肝病杂志.2013,23(2)：117-120.
[50]郭建辉.周仲瑛教授“癌毒学说”新论[J].湖南中医药大学学报.2010,30(11)：6-8.
[51]吴以岭.络病学[M].1.北京：中国科学出版社,2004.
[52]魏睿,王宪波.中医药辨治原发性肝癌：病理因素及用药特点分析[J].中西医结合肝病杂志.2013,23(2)：117-120.
[53]陈赐慧,花宝金.肿瘤炎性微环境与中医阴阳动态平衡关系初探[J].中医杂志.2012,53(19)：1626-1628,1650.
[54]丛玉隆,王淑娟.今日临床检验学[M].1.北京：中国科学技术出版社,1997.
[55]Bingle L, Lewis C, Corker K, et al. Macrophages promote angiogeresis in hrman breast tumour spheroids in vivo[J]. Br J Cancer. 2006,94(1):101-107.
[56]van den Beucken T, Ramaekers C, Rouschop K, et al. Deficient carbonic anhy2drase 9 expression in UPR2impaired cells is associated with reduced survival in an acidic microenvironment[J]. Radiother Oncol. 2009,92(3):437-442.
[57]李以义.痰浊与癌症[J].中国中医基础医学杂志.1995,1(4)：46-47.
[58]王剑,严灿,邓中炎.从粘附分子代谢失常探讨痰证机理[J].中国中西医结合杂志.2000,20(4)：296.
[59]魏录翠,韦艾凌,唐健,等.癌痛消颗粒调节大鼠移植性肝癌VEGF和MVD表达的实验研究[J].辽宁中医药大学学报.2008,10(8)：159-161.
[60]费新应,黄廷荣,沈震,等.膈下逐瘀汤辅助治疗原发性肝癌的临床观察[J].湖北中医杂志.2006,28(1)：34.
[61]韦艾凌,唐健,陈逸恒,等.癌痛消颗粒治疗原发性肝癌血瘀毒结兼正虚证疗效分析[J].辽宁中医杂志.2007,34(5)：570-572.
[62]王庆高,韦艾凌,徐志新.广西中医药[J].2005,28(2)：45-48.
[63]贾中芝,冯耀良,施海彬.原发性肝癌TACE前后血清HIF-1α与VEGF的相关性[J].中国介入影像与治疗学.2010,7(2)：117-120.
[64]黄峰.基于“治未病”思想的癌痛消方防治大鼠诱导性肝癌的实验研究[D].湖南：湖南中医药大学,2013.
[65]刘亚梅.中医热证本质研究进展及思考[J].安徽中医学院学报.1999,18(2)：54-58.
[66]Zhang Y, Wang S, Li Y, et al. Sophocarpine and matrine inhibit the production of TNF-alpha and IL-6 inmurine macrophages and prevent cachexia-related symptoms induced by colon 26 adenocarinoma in mice [J]. Int Immunopharmacol.2008,8(13-14):1767-1772.
[67]Chen X, Mellon R, Yang L, et al. Regulatory effects of deoxycholic acid, a componet if the anti-inflammatory traditional Chinese medicine Niuhuang, on human leukocyte response to chemoattractants[J]. Biochem Pharmacol.2002,63(3):533-541.
[68]丁志山,高承贤,陈铌铍,等.姜黄素具有抑制血管生成与诱导肿瘤细胞凋亡双重作用[J].中国药理学通报.2003,19(2)：171-173.
[69]刘锦蓉,叶松柏.川芎嗪抗肿瘤转移作用及其机理[J].中国药理学与毒理学杂志.1993,7(02)：149-152.
[70]黄孔威,傅乃武.赤芍对实验肿瘤生长和转移的影响及药理作用 的研究[J].中华肿瘤杂志.1983,5(1)：24-27.
[71]郑红刚,朴炳奎,林洪生,等.肺瘤平膏对非小细胞肺癌患者树突状细胞亚型及免疫功能的影响[J].北京中医.2007,26(4)：214-217.
[72]朱峰,杨小伟,汤永辉,等.Walker-256大鼠移植性肝癌模型探讨[J].医学研究杂志.2010,39(9)：92-93.
[73]袁利超,党双锁,程延安.肝癌的靶向治疗[J].世界最新医学信息文摘.2003,2(6)：881-883.
[74]马曾辰.可供临床研究的常用鼠肝癌模型[J].国外医学肿瘤学分册.1982,1(1)：13.
[75]Bertout J A, Patel S A, Simon M C. The impact of 02 availability on human cancer[J]. Nat Rev Cance.2008,8(12):967-975.
[76]Simon J M. Hypoxia and angiogenesis[J]. Bull Cancer.2007.
[77]Vooijs M A, Gort E H, Groot A J, et al. Hypoxic regulation of metastasis viaHypxxia-inducible factors[J]. Curr Mol Med.2008,8(1): 60-67.
[78]Vengellur A, Phillips J M, Hogenesch J B, et al. Gene expression profiling of hypoxia signaling in human hepatocellular carcinoma cells [J]. 2005,22(3):308-318.
[79]Covello K L, Simon M C, Keith B. Targeted replacement of hypoxia-inducible factor-2alpha by a hypoxia inducible factor-2alpha knock in allele promotes tumor growth[J]. Cancer Res.2005,65(6): 2277-2286.
[80]Miyoshi A, Kitajima Y, Ide T, et al. Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1 α-independent manner[J]. Int J Oncol.2006,29(6):1533-1539.
[81]Esteban M A. Regulation of E-cadherin expression byVAL and hypoxia-inducible factor[J]. Cancer Res.2006,66(7):3567-3575.
[82]Mathonnet M, Descottes B, Valleix D, et al. Quantitative analysis using ELISA of vascular endothelial growth factor and basic fibroblast growth factor in human colorectal cancer, liver metastasis of colorectal cancer and hepatocellular carcinoma[J]. World J Gastroenterol.2006, 12(23):3782-3783.
[83]Vumbaca F, Phoenix K N, Rodriguez-Pinto D, et al. Double-Stranded RNA-Binding Protein Regulates Vascular Endothelial Growth Factor mRNA Stability, Translation, and Breast Cancer Angiogenesis.2008,28(2):772-783.
[84]黄峰,韦艾凌.癌痛消颗粒对移植性肝癌模型大鼠肝癌组织mi RNAs表达的影响[J].中国药学杂志.2013,48(20)：1740-1743.
[85]韩克起,凌昌全.中药体外抗肿瘤效应血清药理学研究现状与前景[J].中国中西医结合杂志.2003,23(9)：717-719.
[86]Yan M., Rayoo M., Takano Ea. BRCAI tumours eorrelate with a HIF-1 alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression[J]. Br J Cancer.2009,101(7): 1168-1174.
[87]吕修臣,刘俊莉,张琼霞,等.中西医结合强化综合治疗原发性肝癌临床研究[J].中国中西医结合急救杂志.2001,8(5)：306-308.
[88]Breier G, Licht A H, Nicolaus A, et al. HIF in vascular development and tumour angiogenesis[J]. Novartis Found Symp.2007,283:126-133.
[89]Esteban M A, Tran M G B, Harten S K, et al. Regulation of E-cadherin Expression by VHL and Hypoxia-Inducible Factor[J]. Cancer Res.2006,66(7):3567-3575.
[90]Miyoshi A, Kitajima Y, Ohtaka K, et al. Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MM expression in an HIF-1 α-independent manner[J]. Int J Oncol.2006,29(6):1533-1539.
[91]Park Y, Kin Y. Inereased exppression of vaseular endothelial growth faetor and angiogenesis in the early stage of multistep hepatoeareinogenesis [J]. Arch Pattol Lab Med.2000,124(7):61-106.
[92]盛庆丰,咸华,印其友.二氯化钴诱导大鼠肝癌细胞缺氧与凋亡和增殖的研究[J].南通大学学报(医学版).2008,28(5)：324-325,328.
[1]Whittaker S, Marais R, Zhu A. The role of signaling pathways in the development and treatment of hepatocellular carcinoma[J]. Oncogene. 2010,29:4989-5005.
[2]Yang J, Roberts L. Hepatocellular carcinoma:a global view[J]. Nat Rev Gastroenterol Hepatol.2010,7(8):448-458.
[3]张焕荣,张俊芳,张培帅.肝细胞癌的诊治进展[J].中国当代医药.2012,19(20)：16-18.
[4]韩泽广.肝癌基因组学研究进展[J].中国科学(C辑：生命科学).2008,38(10)：907-912.
[5]Ahmed R, Salama H, Fouad A, et al. Detection of aberrant p16INK4A methylation in sera of patients with HCV-related liver diseases:An Egyptian study[J]. Med Sci Monit.2010,16(9):R410-R415.
[6]Nakagawa T, Kanai Y, Ushijima S, et al. DNA hypomethylation on pericentromeric satellite regions significantly correlates with loss of heterozygosity on chromosome 9 in urothelial carcinomas [J]. J Urol. 2005,173(1):243-246.
[7]Wong N, Lam W, Lai P, et al. Hypomethylation of Chromosome 1 Heterochromatin DNA Correlates with q-Arm Copy Gain in Human Hepatocellular Carcinoma[J]. Am J Pathol.,159(2):465-471.
[8]Guo M, Ren J, Qi M H, et al. Accumulation of Promoter Methylation Suggests Epigenetic Progression in Squamous Cell Carcinoma of the Esophagus[J]. Clin Cancer Res.2006,12(15): 4515-4522.
[9]王勇.肝癌DNA甲基化的研究进展[J].医学综述.2011,17(22)：3404-3406.
[10]Trankenschuh W, Puls F, Christgen M, et al. Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver[J]. PLoS One.2010,5(10):136-188.
[11]Formeister E, Tsuchiya M, Fujii H, et al. Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma[J]. Mutat Res.2010,692(1/2):26-33.
[12]颜见,姚志成,邓美海.乙型肝炎病毒相关性肝癌发生的分子机制研究进展[J].中华普通外科学文献(电子版).2012,06(5)：50-54.
[13]Gu J, Tamura M, Yamada K. Tumor suppressor PTEN inhibits integrin-and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways[J]. J Cell Biol.1998,143(5):1375-1383.
[14]Zhu X, Zhou F, Qin D, et al. Human Immunodeficiency Virus Type 1 Induces Lytic Cycle Replication of Kaposi's-Sarcoma-Associated Herpesvirus:Role of Ras/c-Raf/MEK1/2, PI3K/AKT, and NF-κB Signaling Pathways[J]. J Mol Biol.2011,410(5):1035-1051.
[15]Gomes C, Diniz M, Oliveira C, et al. Impact of WWOX alterations on p73, △Np73, p53, cell proliferation and DNA ploidy in salivary gland neoplasms[J]. Oral Dis.2011,17(6):551-564.
[16]Wang F, Denison S, Lai J, et al. Parkin gene alterations in hepatocellular carcinoma[J]. Genes Chromosomes Cancer.2004,40(2): 85-86.
[17]冯华,任春慧,王凤爽.肝细胞癌发病机制的研究进展[J].牡丹江医学院学报.2007,28(4)：86-88.
[18]Sansal I, Sellers W. The biology and clinical relevance of the PTEN tumor suppressor pathway [J]. J Clin Onco.2004,22(14):2954-2963.
[19]刘志磊,孙薇,贺福初,等.肝细胞癌的微环境研究进展[J].生物化学与生物物理进展.2012,39(05)：416-422.
[20]Bissell M, Hines W. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression[J]. Nat Med. 2011,17(3):320-329.
[21]Mbeunkui F, Johann Jr D. Cancer and the tumor microenvironment: a review of an essential relationship[J]. Cancer Chemother Pharmacol. 2009,63(4):571-582.
[22]Huang G, Chen L. Tumor Vasculature and Microenvironment Normalization:A Possible Mechanism of Antiangiogenesis Therapy [J]. 2008,23(5):661-667.
[23]Hede K. Environmental protection:studies highlight importance of tumor microenvironment[J]. J Natl Cancer Inst.2004,96(15):1120-1121.
[24]Bangoura G, Liu Z, Qian Q, et al. Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma[J]. World J Gastroenterol.2007,13(23):3176-3182.
[25]Gwak G, Yoon J, Kim K, et al. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression[J]. J Hepatol.2005,42(3):358-364.
[26]Kim K, Moon H, Kim K. Hypoxia-induced angiogenesis in human hepatocellular carcinoma[J]. J Mol Med.2002,80(11):703-704.
[27]Miyoshi A, Kitajima Y, Ide T, et al. Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1 α-independent manner[J]. Int J Oncol.2006,29(6):1533-2539.
[28]Wu X, Xie G, Chen D. Hypoxia and hepatocellular carcinoma:The therapeutic target for hepatocellular carcinoma[J]. J Gastroentero 1 Hepatol.2007,22(8):1178-1182.
[29]Bertout J, Patel S, Simon M. The impact of 02 availability on human cancer[J]. Nat Rev Cancer.2008,8(12):967-975.
[30]Rosmorduc O, Housse C. Hypoxia:a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease[J]. Semin Liver Dis. 2010,30(3):258-270.
[31]Paternostro C, David E, Novo E, et al. Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases[J]. World J Gastroentero 1.2010,16(3):281-288.
[32]王照红,王志明.肝细胞癌缺氧微环境下PHD2的表达及其与血管生成的关系[J].中国普通外科杂志.2010,19(10)：1113-1117.
[33]Folkman J. Angiogenesis:an organizing principle for drug discovery?[J]. Nat Rev Drug Discov.2007,6:273-286.
[34]Quesada A, Medina M, Alba E. Playing only one instrument may be not enough:limitations and future of the antiangiogenic treatment of cancer[J]. Bioessays.2007,29(11):1159-1168.
[35]Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy[J]. Nat Rev Cancer,2008,8(8):592.2008,8:592-603.
[36]Fukumura D, Jain R. Tumor micro vasculature and microenvironment:targets for anti-angiogenesis and normalization [J]. Microvasc Res.2007,74(2-3):72-84.
[37]Lin M, Sessa W. Antiangiogenic therapy:Creating a unique "window" of opportunity [J]. Cancer cell.2004,6(6):529-531.
[38]Jain R, Duda D, Clark J, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer[J]. Nat Clin Pract Oncol.2006,3(1): 24-40.
[39]Tong R, Boucher Y, Kozin S, et al. Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors[J]. Cancer Res.2004,64(11):3731-3736.
[40]张丽,张华.中医姑息治疗肝癌[J].现代中西医结合杂志.2007,16(11)：1475-1477.
[41]闫建国,姚树坤.中医对原发性肝癌的辨证研究及治疗[J].中西医结合肝病杂志.2010,20(3)：189-191.
[42]黄金昶.原发性肝癌中医治疗体会[J].中国临床医生.2006,34(10)：59-60.
[43]张洪亮,张震中,王登正.肝癌[J].新疆中医药.2005,23(02)：74-76.
[44]谢晶日,赵刚,梁国英.原发性肝癌的中医药现代研究进展[J].中国医药导报.2008,5(7)：17-18.
[45]孙佳,叶丽红.名老中医治疗肝癌经验研究评述[J].中医学报.2012,27(6)：658-660.
[46]王睿林,王立福,王仲霞,等.中药治疗肝癌研究现状[J].传染病信息.2012,25(3)：189-192.
[47]王见义,赵莹,王灵台.王灵台治疗原发性肝癌经验探微[J].上海中医药杂志.2010(02)：20-21.
[48]王昌俊,陈伟.钱伯文治疗原发性肝癌经验[J].中医杂志.1999,40(08)：460-461.
[49]金萍,沈敏鹤.吴良村诊治原发性肝癌经验[J].中医杂志.2005,46(9)：660-661.
[50]陈华良.周岱翰治肝癌临证经验[J].中医杂志.2003,44(12)：894-895.
[51]范先基,杨子玉.王三虎治疗肝癌经验[J].中国中医药信息杂志.2009,16(8)：86-87.
[52]周滢,周萍.邓中甲教授治疗肝癌经验分析[J].中国实验方剂学杂志.2012,18(2)：260-261.
[53]赵冬耕,叶丽红.肝癌中医研究近况[J].辽宁中医药大学学报.2011,13(12)：207-209.
[54]李涵.中医药治疗原发性肝癌的临床应用进展[J].中医临床研究.2012,04(16)：114-117.
[55]侯风刚,凌昌全,赵钢,等.原发性肝癌中医基本证候临床分布状况调查分析[J].上海中医药杂志.2005,39(2)：22-23.
[56]李永健,方肇勤,邸若虹,等.2492例肝癌辨证分型临床报道的统计分析[J].中国中医基础医学杂志.2001,7(6)：69-71.
[57]燕忠生,魏千程,张慧渊,等.原发性肝癌中医证型临床特点与预后关系研究[J].实用中医内科杂志.2006,20(4)：411-412.
[58]庄险峰.“三辨”治肝癌[J].中医临床研究.2012(18)：18-20.
[59]熊智波.益气养阴解毒法治疗原发性肝癌的研究与应用[J].湖北中医杂志.2011,33(4)：68-69.
[60]孙振,王忠.肝癌中医治法研究概述[J].浙江中医药大学学报.2011,35(3)：468-470.
[61]佟晓光,张景洲,惠歌.以通络学说论治肝细胞癌的探讨[J].中国医药指南.2012,10(21)：261-262.
[62]袁菊花,吴煜.肝癌从痰论治[J].新中医.2012,44(03)：131-132.
[63]杨勤龙.大黄甲虫汤治疗原发性肝癌30例临床报告[J].黑龙江中医药.2001,10(05)：28-29.
[64]彭海燕,章永红,王瑞平,等.补肝软坚方治疗肝癌100例临床观察[J].北京中医.2004,23(1)：30-31.
[65]傅理琦.扶正抑瘤汤治疗晚期肝癌42例临床观察[J].浙江中医杂志.2001,36(9)：375-376.
[66]李江,谢鸣,甘媛.小柴胡汤及其药群配伍抗小鼠H22肝肿瘤及免疫调节作用[J].中国中药杂志.2008,33(9)：1039-1044.
[67]季幸妹,周小军,侯丽颖,等.膈下逐瘀汤对肝癌防治的机理研究[J].现代医药卫生.2008,24(12)：1742-1744.
[68]杜标炎,张爱娟,谭宇蕙,等.六味地黄丸对自杀基因系统杀伤肝癌细胞增效作用的量效关系[J].广州中医药大学学报.2009,26(1)：59-62.
[69]刘俊保,姚志伟.白花蛇舌草注射液对原发性肝癌的临床作用[J].医药论坛杂志.2004,25(15)：37,39.
[70]蒋明东,李少林.三氧化二砷与肝癌治疗的研究进展[J].重庆医学.2006,35(6)：558-559,563.
[71]代志军,刘小旭,薛茜,等.半枝莲含药血清对小鼠肝癌细胞生长的抑制和诱导凋亡作用[J].中药材.2008,31(4)：550-553.
[72]荆绪斌,李涛,杨绮华,等.汉防己甲素抑制肝癌细胞增生的作 用[J].世界华人消化杂志.2003,11(8)：1223-1226.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |